|
|
 |
|
Viewing report
|
|
|
|
Prostate Cancer - A Therapeutic & Competitive Insight
Bioseeker, Jan 2007, Pages: 99
Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. Several new approvals have changed the panorama for options in the treatment of late stage prostate cancer. Abarelix was approved in November 2003 for the palliative treatment of men with advanced symptomatic prostate cancer. In May 2004 docetaxel was approved for use in combination with prednisone as a treatment for patients with androgen independent (hormone refractory) metastatic prostate cancer. Additionally, in October 2004 FDA approved histrelin for the palliative treatment of advanced prostate cancer. Finally, leuprolide was approved by FDA in January 2002 for the palliative treatment of advanced prostate cancer. One example of market penetration in this field is that analysts forecasts Abarelix a sales of $450 million in 2006.
Research and analysis highlights
In the report 'Prostate Cancer - A Therapeutic & Competitive Insight' we do not only describe and analyze the latest years of progress but as well provide an insight and framework to understand the complex field of prostate cancer therapeutics. In this report, we provide one of the most comprehensive coverage of the R&D trends to set the future marketplace. We present both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. We have identified 127 drug candidates in phase II or III stage of development and more than 85 companies are involved in the development of these drugs. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in this market and current treatments will be changed for the benefit of more innovative therapies.
Scope of this report
- Thorough examination of status and impact of several novel drugs in development
- Discussion of the challenges in current and future treatment strategies
- Anticancer pipeline of most companies in the field
Key reasons to read this report
- Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in prostate cancer R&D, and the results of clinical trials to date
- Gain insight into the current challenges and commercial opportunities associated with prostate cancer therapy
- One hundred high quality references
Some of the drugs included in this analysis:
toremifene, bevacizumab, oblimersen sodium, R-flurbiprofen, sipuleucel-T, satraplatin, GVAX, exisulind, vapreotide, DCVax-prostate, epothilone D, ixabepilone, PTK/ZK, arsenic trioxide,retinoic acid, imatinib, bortezomib, sorafenib tosylate, doxorubicin etc.
Customers who bought this item also bought
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer
Prostate and Breast Cancer- New Treatments & Developmental Progress
Prostate Cancer Therapeutics - Global Strategic Business Report
Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs
Analytical Tool - Prostate Cancer
Drugs of Tomorrow 2000: Prostate Cancer - Hormonals and Beyond
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
Cancer Prostate Cancer
Chinese Markets for Prostate Cancer Treatment Drugs
Pipeline Insight: Prostate Cancer - Domination By The Innovative Classes
Analytical Tool - Prostate Cancer: A Therapeutic & Competitive Insight
Top 7 Cancer Indications - Therapeutic & Competitive Insights
|
|
|
|
